BEAUTYFARM MED (02373) announced that the Group expects to achieve revenue of not less than RMB 3 billion in 2025, representing a year-on-year increase of not less than 16% compared to 2024. The adjusted net profit is anticipated to be not less than RMB 380 million, marking a growth of not less than 40% compared to the same period in 2024. The net profit is projected to be not less than RMB 340 million, an increase of not less than 34% year-on-year.

The Board of Directors attributes the performance improvement primarily to the following reasons: 1) Accelerated external expansion: As an industry leader accelerating the industry consolidation process, the acquisition of Nairui'er, the second-ranked brand in China's beauty industry, has enhanced market share and boosted the Group's revenue and profit. 2) Strong internal growth: The expansion of brand momentum and growth in customer numbers have driven internal revenue growth, coupled with an increased proportion of high-margin medical business revenue and the release of refined operational efficiency, collectively driving further profit margin growth.

The announcement stated that the Group will continue to implement its dual-drive strategy of "internal growth + external acquisition," persistently deepening its "dual beauty + dual healthcare" business model. With the implementation of the Group's plan to enhance its capital market value, it aims to create a sustainable and mutually beneficial future for customers, employees, and shareholders.